This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Allscripts (MDRX) Misses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Significant margin contraction hurts Allscripts' (MDRX) results in Q3; decline in bookings discourages.
Tandem Diabetes (TNDM) Reports Loss in Q3, Revenues Beat
by Zacks Equity Research
Impressive domestic sales along with the recent launch of the t:slim X2 Insulin Pump in select international markets drove Tandem Diabetes' (TNDM) revenue beat in Q3.
Masimo (MASI) Beats on Q3 Earnings, 2018 Guidance Impressive
by Zacks Equity Research
Masimo (MASI) gains from strong Product revenues in Q3; raises 2018 outlook.
Abiomed (ABMD) Q2 Earnings Beat, Impella Maintains Momentum
by Zacks Equity Research
Abiomed's (ABMD) flagship Impella sees a solid Q2; fiscal 2019 outlook raised.
Bruker (BRKR) Q3 Earnings Surpass Estimates, Guidance Up
by Zacks Equity Research
We are upbeat about Bruker's (BRKR) current focus on product development through higher R&D.
Teleflex (TFX) Q3 Earnings Surpass Estimates, EPS View Up
by Zacks Equity Research
Teleflex (TFX) consistently rides high on a robust uptick in revenues, backed by stable segmental growth and solid geographical expansions.
Insulet (PODD) Beats Earnings and Revenue Estimates in Q3
by Zacks Equity Research
We are encouraged by the year-over-year improvement in Insulet's (PODD) Q3 results on solid uptake of Omnipod system in the United States. It is also gaining from pursuing direct European operations.
Bio-Rad (BIO) Earnings Miss Estimates in Q3, Revenues Beat
by Zacks Equity Research
Bio-Rad's (BIO) solid revenue growth in geographies like North America, China and Asia Pacific in Q3 buoys optimism.
IDEXX Laboratories (IDXX) Beats on Q3 Earnings, EPS View Up
by Zacks Equity Research
IDEXX Laboratories' (IDXX) stellar performance in Q3 reflects strong sales at the CAG business.
PerkinElmer (PKI) Misses on Q3 Earnings, Slashes EPS View
by Zacks Equity Research
Perkinelmer (PKI) gains from segmental performances in Q3; lowers 2018 EPS view.
Accuray (ARAY) Q1 Loss Wider Than Expected, Gross Orders Rise
by Zacks Equity Research
Accuray's (ARAY) flagship Radixact System drives Q1 results; strong EBITDA guidance instils hope.
Express Scripts (ESRX) Tops Q3 Earnings & Revenue Estimates
by Zacks Equity Research
Express Scripts' (ESRX) Q3 results hurt by year-over-year decline in adjusted network claims, thanks to the loss of certain public sector clients.
Baxter (BAX) Earnings Beat, Revenues Lag Estimates in Q3
by Zacks Equity Research
Baxter (BAX) gains from Renal Care and Advanced Surgery units in Q3; APAC sales soft.
Cardiovascular Systems' (CSII) Q1 Loss Wider Than Expected
by Zacks Equity Research
Cardiovascular Systems (CSII) sees strength in Coronary device and peripheral device segments in Q1.
NextGen Healthcare (NXGN) Beats on Q2 Earnings, Lags Revenues
by Zacks Equity Research
NextGen Healthcare (NXGN) delivers strong growth in software, hardware and other non-recurring revenues in Q2; lowers fiscal 2019 view.
Fresenius Medical (FMS) Beats on Q3 Earnings, Lags Revenues
by Zacks Equity Research
Lower North America sales hurt Fresenius Medical's (FMS) Q3 results. Care Coordination margin improves significantly.
Amedisys (AMED) Tops Earnings and Revenue Estimates in Q3
by Zacks Equity Research
At the Home Health and Hospice divisions, Amedisys (AMED) gains traction from solid growth in Medicare and non-Medicare revenues in Q3.
Ecolab (ECL) Misses on Q3 Earnings & Revenues, Lowers View
by Zacks Equity Research
Ecolab (ECL) misses estimates despite strong growth in Global Industrial and Global Institutional; 2018 guidance dull.
QIAGEN (QGEN) Beats Earnings and Revenue Estimates in Q3
by Zacks Equity Research
QIAGEN's (QGEN) year-over-year revenue growth in Q3 and operating margin expansion are encouraging.
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Merit Medical (MMSI) Tops Q3 Earnings & Revenue Estimates
by Zacks Equity Research
Merit Medical (MMSI) gains from solid segmental performance in Q3. Also, the company reiterated its guidance for 2018.
Merit Medical (MMSI) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Merit Medical (MMSI) delivered earnings and revenue surprises of 11.90% and 1.86%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Merit Medical (MMSI) Q3 Earnings Preview: Here's What to Look Out For
by Zacks Equity Research
Merit Medical (MMSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
HSIC or MMSI: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HSIC vs. MMSI: Which Stock Is the Better Value Option?
Merit Medical (MMSI) to Acquire Cianna Medical, Shares Up
by Zacks Equity Research
Merit Medical (MMSI) to leverage on Cianna Medical's SAVI and SCOUT platforms. The company plans to retain Cianna Medical's commercial and R&D teams after closure of the transaction.